Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290382 | 0.83 | TSHR (0.59) | MAPTLMNAMEN1FAAHMAPK1 | |
| SCHEMBL5909062 | 0.82 | MEN1 (0.62) | MAPTMEN1FAAHMAPK1KMT2A | |
| SCHEMBL72471 | 0.82 | LMNA (0.62) | MAPTLMNATSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL878351 | 0.81 | MAPT (0.51) | MAPTLMNATSHRHTT | |
| SCHEMBL13043728 | 0.80 | MAPT (0.44) | MAPTLMNATSHRSMN1; SMN2HTT | |
| SCHEMBL31402602 | 0.79 | LMNA (0.60) | MAPTLMNATSHRALDH1A1HTT | |
| SCHEMBL1979159 | 0.78 | TSHR (0.65) | MAPTLMNAMEN1KMT2ATSHR | |
| SCHEMBL8236193 | 0.78 | KMT2A (0.53) | MAPTLMNAMEN1FAAHMAPK1 | |
| SCHEMBL26242694 | 0.76 | MAPT (0.47) | MAPTLMNATSHRHPGDSMN1; SMN2 | |
| SCHEMBL13815218 | 0.76 | GAA (0.39) | MAPTLMNAMEN1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145398-A1 | ANTIBODY DRUG CONJUGATES | YALE UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230257587-A1 | FLUORENYL CYANINE DYES | BIOTIUM, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20180156810-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9791450-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170247402-A1 | HETEROCYCLE-SUBSTITUTED XANTHENE DYES | BIOTIUM, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9579402-B2 | Heterocycle-substituted xanthene dyes | BIOTIUM, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160033520-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9097667-B2 | Fluorescent compounds | BIOTIUM, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9006437-B2 | Xanthene dyes comprising a sulfonamide group | BIOTIUM, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8436170-B2 | Xanthene dyes comprising a sulfonamide group | BIOTIUM, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110136201-A1 | HETEROCYCLE-SUBSTITUTED XANTHENE DYES | BIOTIUM, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110097735-A1 | FLUORESCENT PYRENE COMPOUNDS | BIOTIUM, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100197030-A1 | XANTHENE DYES COMPRISING A SULFONAMIDE GROUP | BIOTIUM, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | BIOTIUM, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097735-A1 | FLUORESCENT PYRENE COMPOUNDS | PAH, CYP1A1, PYCR1 | MAPT 1563/4885LMNA 86/4885MEN1 2998/4885 |
| US-20100197030-A1 | XANTHENE DYES COMPRISING A SULFONAMIDE GROUP | XDH, ARSA, STS | MAPT 2333/4885LMNA 303/4885MEN1 1823/4885 |
| US-20230257587-A1 | FLUORENYL CYANINE DYES | FPR3, FPR1, TYR | MAPT 1486/4885LMNA 1223/4885MEN1 1931/4885 |
| US-20170247402-A1 | HETEROCYCLE-SUBSTITUTED XANTHENE DYES | XDH, CCKAR, CCKBR | MAPT 2598/4885LMNA 221/4885MEN1 1265/4885 |
| US-20090305410-A1 | FLUORESCENT COMPOUNDS | MKI67, CD68, CA5B | MAPT 924/4885LMNA 539/4885MEN1 1677/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | MAPT 3226/4885LMNA 1695/4885MEN1 41/4885 |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MAPT 2607/4885LMNA 2338/4885MEN1 3725/4885 |
| US-20110136201-A1 | HETEROCYCLE-SUBSTITUTED XANTHENE DYES | XDH, CCKAR, CCKBR | MAPT 2598/4885LMNA 221/4885MEN1 1265/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | MAPT 2603/4885LMNA 3249/4885MEN1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.